Gomez HF, Cleary TG. Shigella species. Principles and Practice of Pediatric Infectious Diseases. New York, NY: Churchill Livingstone; 1997. 429-34.
Phalipon A, Sansonetti PJ. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?. Immunol Cell Biol. 2007 Feb-Mar. 85(2):119-29. [QxMD MEDLINE Link].
Brenner D J ( e book - William B. Whitman). Family 1 : Enterobacteriaceae. Krieg, N.R. & Holt, J.C. (eds., 1984). Bergey's manual of systematic bacteriology. Krieg, N.R. & Holt, J.C. (eds., 1984). e book: (Baltimore, MD : Williams & Wilkins, ©1984-©1989), e book-Bergey¿s Manual Trust 2011; 1984 (e book 2011). Vol 1: 408-420. [Full Text].
Edwards BH. Salmonella and Shigella species. Clin Lab Med. 1999 Sep. 19(3):469-87, v. [QxMD MEDLINE Link].
Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002 Jan 1. 185(1):74-84. [QxMD MEDLINE Link].
Richardson SE, Rotman TA, Jay V, et al. Experimental verocytotoxemia in rabbits. Infect Immun. 1992 Oct. 60(10):4154-67. [QxMD MEDLINE Link].
Ingersoll MA, Zychlinsky A. ShiA abrogates the innate T-cell response to Shigella flexneri infection. Infect Immun. 2006 Apr. 74(4):2317-27. [QxMD MEDLINE Link].
Keusch GT, Jacewicz M, Acheson DW, et al. Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect Immun. 1995 Mar. 63(3):1138-41. [QxMD MEDLINE Link].
Schuller S. Shiga toxin interaction with human intestinal epithelium. Toxins (Basel). 2011 Jun. 3(6):626-39. [QxMD MEDLINE Link].
Crim SM, Iwamoto M, Huang JY, Griffin PM, Gilliss D, Cronquist AB, et al. Incidence and trends of infection with pathogens transmitted commonly through food--Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2006-2013. MMWR Morb Mortal Wkly Rep. 2014 Apr 18. 63 (15):328-32. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention (CDC). National Shigella Surveillance Annual Report, 2012. Atlanta, Georgia: US Department of Health and Human Services, CDC; 2014.
Doore SM, Schrad JR, Dean WF, Dover JA, Parent KN. Shigella phages isolated during a dysentery outbreak reveal uncommon structures and broad species diversity. J Virol. 2018 Feb 7. J Virol. 2018 Feb 7. pii: JVI.02117-17. doi: 10.1128/JVI.02117-17. JVI.02117-17:pii: JVI.02117-17. doi: 10.1128/JVI.02117-17. [QxMD MEDLINE Link].
Arnold SLM. Target product profile and development path for shigellosis treatment with antibacterials. ACS Infect Dis. 2021 May 14. 7 (5):948-58. [QxMD MEDLINE Link].
CDC. Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb Mortal Wkly Rep. 2011 Jun 10. 60(22):749-55. [QxMD MEDLINE Link].
Plotz FB, Arets HG, Fleer A, et al. Lethal encephalopathy complicating childhood shigellosis. Eur J Pediatr. 1999 Jul. 158(7):550-2. [QxMD MEDLINE Link].
Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis. 2006 Feb 1. 42(3):356-62. [QxMD MEDLINE Link].
Tzipori S, Sheoran A, Akiyoshi D, et al. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev. 2004 Oct. 17(4):926-41, table of contents. [QxMD MEDLINE Link].
Baer JT, Vugia DJ, Reingold AL, et al. HIV infection as a risk factor for shigellosis. Emerg Infect Dis. 1999 Nov-Dec. 5(6):820-3. [QxMD MEDLINE Link].
Khan WA, Dhar U, Salam MA, et al. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics. 1999 Feb. 103(2):E18. [QxMD MEDLINE Link].
Tickell KD, Brander RL, Atlas HE, Pernica JM, Walson JL, Pavlinac PB. Identification and management of Shigella infection in children with diarrhoea: a systematic review and meta-analysis. Lancet Glob Health. 2017 Dec. 5 (12):e1235-e1248. [QxMD MEDLINE Link].
Ochoa TJ, Cleary TG. Shigella. Kliegman, Behrman, Jenson, Stanton, eds. Nelson Textbook of Paediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011. 191-Pg 959-961. [Full Text].
Mitra AK, Alvarez JO, Wahed MA, et al. Predictors of serum retinol in children with shigellosis. Am J Clin Nutr. 1998 Nov. 68(5):1088-94. [QxMD MEDLINE Link].
Nataro JP. Treatment of bacterial enteritis. Pediatr Infect Dis J. 1998 May. 17(5):420-1. [QxMD MEDLINE Link].
Rahman MJ, Sarkar P, Roy SK. Effect of zinc supplementation as adjunct therapy on the systemic immune response in shigellosis. Am J Clin Nutr. Feb, 2005. 81(2):495-502. [QxMD MEDLINE Link].
World Health Organization. Zinc in a diarrhoeal disease control programme. 2008. Available at http://whqlibdoc.who.int/publications/2008/9789241596473_eng.pdf. Accessed: June 19, 2012.
Goodridge LD. Bacteriophages for managing Shigella in various clinical and non-clinical settings. Bacteriophage. 2013;3(1):e25098. doi:10.4161/bact.25098. Goodridge LD. Bacteriophages for managing Shigella in various clinical and non-clinical settings. Bacteriophage. 2013;3(1):e25098. doi:10.4161/bact.25098. Bacteriophage. 2013 Jan 1; 3(1): e25098. 2013 Jan 1; 3(1): e25098. doi:10.4161/bact.25098. 2013;3(1):e25098.:[QxMD MEDLINE Link]. [Full Text].
Fogg PCM, Rigden DJ, Saunders JR, McCarthy AJ, Allison HE. Characterization of the relationship between integrase, excisionase and antirepressor activities associated with a superinfecting Shiga toxin encoding bacteriophage. Nucleic Acids Research. 2011 Mar:Published online 2010 Nov 8. doi: 10.1093/nar/gkq923. 2011;3 , 39(6):2116–2129. [QxMD MEDLINE Link].
Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010 Aug 4. CD006784. [QxMD MEDLINE Link].
Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J. 2003 Apr. 22(4):374-7. [QxMD MEDLINE Link].
Niyogi SK. Shigellosis. J Microbiol. 2005 Apr. 43(2):133-43. [QxMD MEDLINE Link].
Heiman KE, Karlsson M, Grass J, Howie B, Kirkcaldy RD, Mahon B, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2014 Feb 14. 63(6):132-3. [QxMD MEDLINE Link].
Brooks M. Growing Concern Over Drug-Resistant Shigella in US. Medscape Medical News. Available at http://www.medscape.com/viewarticle/846038. June 06, 2015; Accessed: April 22, 2016.
Ciprofloxacin- and Azithromycin-Nonsusceptible Shigellosis in the United States. Centers for Disease Control and Prevention. Available at http://www.bt.cdc.gov/han/han00379.asp. June 4, 2015; Accessed: April 22, 2016.
Bowen A, Eikmeier D, Talley P, Siston A, Smith S, Hurd J, et al. Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep. 2015 Jun 5. 64 (21):597-8. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Increase in extensively drug-resistant shigellosis in the United States. CDC Health Alert Network. Available at https://emergency.cdc.gov/han/2023/pdf/CDC_HAN_486.pdf. 2023 Feb 24; Accessed: March 2, 2023.
Appannanavar SB, Goyal K, Garg R, Ray P, Rathi M, Taneja N. Shigellemia in a post renal transplant patient: a case report and literature review. J infect Dev Ctries. Feb 13, 2014. 8:237-239. [QxMD MEDLINE Link].
World Health Organization. Implementing the new recommendations on the clinical management of diarrhea. 2006. Available at http://whqlibdoc.who.int/publications/2006/9241594217_eng.pdf. Accessed: June 19, 2012.
Katz DE, Coster TS, Wolf MK, et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun. 2004 Feb. 72(2):923-30. [QxMD MEDLINE Link].
Wu T, Grassel C, Levine MM, Barry EM. Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit. Infect Immun. 2011 Dec. 79(12):4912-22. [QxMD MEDLINE Link]. [Full Text].
National Institute of Allergy and Infectious Diseases (NIAID). Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3. Available at http://clinicaltrials.gov/ct2/show/NCT01336699. Accessed: June 6, 2014.
World Health Organization. Guidelines for the control of Shigellosis, including epidemics due to Shigella dysenteriae type 1. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf. Accessed: June 19, 2012.